Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatitis B antibody persistence and challenge response after 4-dose Infanrix hexa vaccination in children aged 4-6 years
2006-000553-22Phase 4Completed
- Sponsor
- GSK
- Start
- May 2006
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hepatitis B vaccine recombinant in hepatitis B (HBV), sponsored by GSK. Primary endpoints: Anti-HBs antibody response one month after challenge dose and Persistence of anti-HBs antibodies at 4-6 years of age. Started May 2006; status: completed.
02
Drugs
hepatitis B vaccine recombinant
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2006-000553-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000553-22.